NDA 022362 · Cosette
Welchol
Colesevelam Hydrochloride · Oral
Last checked: Nov 19, 2026Latest source record: Oct 20, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Oct 2, 2009
Approved uses
2
Original approval plus efficacy supplements
Registered trials
55
12 Phase 3, 3 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 20, 2021 Supplement 29 · Efficacy LabelLetter
- Oct 2, 2009 Original approval · Type 3 - New Dosage Form ReviewPediatric Written RequestPediatric Amendment 1
2 products under this application
- WELCHOL · COLESEVELAM HYDROCHLORIDE 1.875GM/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · FOR SUSPENSION, ORAL · Discontinued
- WELCHOL · COLESEVELAM HYDROCHLORIDE 3.75GM/PACKET · FOR SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Colesevelam" as an intervention, any sponsor and status, largest first.
- Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 DiabetesPivotal-lookingCompleted
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT00151762 · 780 participants · Start Dec 2004 · Primary completion Jul 2007
Drug: Colesevelam hydrochloride · For: Type 2 Diabetes
Sites: Birmingham, Alabama; Tuscumbia, Alabama; Jonesboro, Arkansas · 64 sites in all
- Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes MellitusPivotal-lookingCompleted
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT00789750 · 562 participants · Start Apr 2009 · Primary completion Jul 2012
Drug: Colesevelam; Placebo and 1 more · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Montgomery, Alabama; Green Valley, Arizona · 141 sites in all
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT00570739 · 502 participants · Start Nov 2007 · Primary completion Apr 2009
Drug: Metformin HCl and Colesevelam Placebo; Metformin HCl tablets and Colesevelam tablets and 2 more · For: Type 2 Diabetes Mellitus; Hypercholesterolemia; Pre-diabetes
Sites: Birmingham, Alabama; Los Gatos, California; Tarzana, California · 31 sites in all
- WelChol® and Sulfonylurea in Treating Patients With Type 2 DiabetesPivotal-lookingCompleted
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT00147758 · 400 participants · Start Jun 2004 · Primary completion Aug 2006
Drug: Colesevelam hydrochloride · For: Type 2 Diabetes
Sites: Birmingham, Alabama; Tuscumbia, Alabama; Little Rock, Arkansas · 47 sites in all
- Welchol as Monotherapy for Type 2 Diabetes MellitusPivotal-lookingCompleted
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT00789737 · 357 participants · Start Jan 2009 · Primary completion Dec 2011
Drug: Welchol; Placebo · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Montgomery, Alabama; Muscle Shoals, Alabama · 107 sites in all
- WelChol® With Metformin in Treating Patients With Type 2 DiabetesPivotal-lookingCompleted
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT00147719 · 300 participants · Start Jun 2004 · Primary completion Jul 2006
Drug: Colesevelam hydrochloride · For: Type 2 Diabetes
Sites: Jonesboro, Arkansas; Beverly Hills, California; Carmichael, California · 48 sites in all
- WelChol® and Insulin in Treating Patients With Type 2 DiabetesPivotal-lookingCompleted
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT00151749 · 260 participants · Start Jun 2004 · Primary completion Dec 2005
Drug: Colesevelam hydrochloride · For: Type 2 Diabetes
Sites: Tuscumbia, Alabama; Sierra Vista, Arizona; Jonesboro, Arkansas · 47 sites in all
- Effect of the Sequestrant Colesevelam in Bile Acid DiarrhoeaPivotal-lookingCompleted
Lars Kristian MunckAcademic, hospital or other
NCT03876717 · 255 participants · Start Oct 25, 2018 · Primary completion Jul 1, 2021
Drug: Colesevelam Hydrochloride; Placebo oral capsule · For: Bile Acid Malabsorption; Chronic Diarrhea
Sites: Aalborg, Denmark; Aarhus, Denmark; Hvidovre, Denmark · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Welchol (Colesevelam HCl)
2024 spending
$4.2M
Beneficiaries
1,154
3,853 claims
Per beneficiary
$3,616
$6.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $78,099,195 |
| 2021 | $38,543,912 |
| 2022 | $22,576,603 |
| 2023 | $9,688,073 |
| 2024 | $4,172,400 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A randomized double-blind trial of clonidine and colesevelam for women with fecal incontinence.
Varma R, Feuerhak KJ, Mishra R, et al. · Neurogastroenterol Motil 2024 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Colesevelam for type 2 diabetes mellitus.
Ooi CP, Loke SC · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Prospective comparison of diagnostic tests for bile acid diarrhoea.
Borup C, Vinter-Jensen L, Jørgensen SPG, et al. · Aliment Pharmacol Ther 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- An evidence-based review of systemic treatments for itch.
Pongcharoen P, Fleischer AB · Eur J Pain 2016 · Meta-Analysis, Systematic Review
- Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics.
Jones MR, Baker BA, Mathew P · Clin Pharmacokinet 2004 · Clinical Trial, Comparative Study
- Colesevelam has no acute effect on postprandial GLP-1 levels but abolishes gallbladder refilling.
Gether IM, Bahne E, Nerild HH, et al. · Eur J Endocrinol 2024 · Randomized Controlled Trial
Sponsor: Cosette
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.